within Pharmacolibrary.Drugs.ATC.A;

model A06AH04
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0003733333333333333,
    adminDuration  = 600,
    adminMass      = 0.4 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0088,
    k12             = 1.6,
    k21             = 1.6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A06AH04</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Naloxone is an opioid antagonist used primarily to rapidly reverse opioid overdose. It binds to opioid receptors and can reverse and block the effects of other opioids, including respiratory depression, sedation, and hypotension. Naloxone is approved and widely used today both in emergency settings and by bystanders.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after intravenous administration.</p><h4>References</h4><ol><li><p>Saari, TI, et al., &amp; Dale, O (2024). Clinical Pharmacokinetics and Pharmacodynamics of Naloxone. <i>Clinical pharmacokinetics</i> 63(4) 397–422. DOI:<a href=\"https://doi.org/10.1007/s40262-024-01355-6\">10.1007/s40262-024-01355-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38485851/\">https://pubmed.ncbi.nlm.nih.gov/38485851</a></p></li><li><p>Wahler, BM, et al., &amp; Aarnes, TK (2019). Pharmacokinetics and pharmacodynamics of intranasal and intravenous naloxone hydrochloride administration in healthy dogs. <i>American journal of veterinary research</i> 80(7) 696–701. DOI:<a href=\"https://doi.org/10.2460/ajvr.80.7.696\">10.2460/ajvr.80.7.696</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31246123/\">https://pubmed.ncbi.nlm.nih.gov/31246123</a></p></li><li><p>Dowling, J, et al., &amp; Graudins, A (2008). Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. <i>Therapeutic drug monitoring</i> 30(4) 490–496. DOI:<a href=\"https://doi.org/10.1097/FTD.0b013e3181816214\">10.1097/FTD.0b013e3181816214</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18641540/\">https://pubmed.ncbi.nlm.nih.gov/18641540</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A06AH04;
